Published: 2022-04-25

Progressive familial intrahepatic cholestasis-2 and concomitant cytomegalovirus infection in an infant: a case report

Ananya Mukherjee, Nithin Veluru, Pradeep Kumar Ranabijuli, Anil Tambe


Conjugated hyperbilirubinemia (CH) in infancy can have anatomic, infectious, auto-immune and metabolic causes. We reported a case of CH presented at 2 months and 20 days, with clinical jaundice and evidence of acute on chronic liver failure. Significant history of elder sibling death at the age of 5 months due to hepatic failure and intracranial bleed was present. Investigations revealed a normal gamma glutamyl transpeptidase (GGT) levels. Toxoplasmosis, rubella, cytomegalovirus and herpes simplex (TORCH) panel showed cytomegalovirus (CMV) immunoglobulin M (IgM), immunoglobulin G (IgG) and deoxyribonucleic acid polymerase chain reaction (DNA PCR) positive with mother’s serum CMV IgG, so she was started on oral valganciclovir in addition to other treatment for cholestasis. A clinical exome panel was also sent which showed homozygous two base-pair deletion in exon 27 of the ABCB11 gene [c.3659 3660del (p.Ser1220Ter)] suggestive of benign recurrent intrahepatic cholestasis (BRIC)/progressive familial intrahepatic cholestasis-2 (PFIC-2). The child responded initially to treatment showing reduced serum conjugated bilirubin level and near normalization of INR. However, she was re-admitted with deranged coagulation profile and rising conjugated bilirubin levels after 30 days of discharge and expired due to fulminant hepatic failure with encephalopathy at 6 months of age while she was being prepared for live donor (father) liver transplantation. We presented this case because we found evidence of CMV infection in a child with PFIC-2. The relative contribution of either aetiology needs to be ascertained in view of early recurrence of CH despite standard management protocol including oral valgancyclovir for CMV infection.


PFIC-2, Cytomegalovirus, Neonatal cholestasis, Conjugated hyperbilirubinemia

Full Text:



Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(1): 26-35.

Hasosah MY, Kutbi SY, Al-Amri AW, Alsahafi AF, Sukkar GA, Alghamdi KJ, et al. Perinatal cytomegalovirus hepatitis in Saudi infants: A case series. Saudi J Gastroenterol. 2012;18:208-13.

Agarwal S, Lal BB, Rawat D, Rastogi A, Bharathy KG, Alam S. Progressive Familial Intrahepatic Cholestasis (PFIC) in Indian Children: Clinical Spectrum and Outcome. J Clin Exp Hepatol. 2016;6(3):203-8.

Bilavsky E, Schwarz M, Bar-Sever Z, Pardo J, Amir J. Hepatic involvement in congenital cytomegalovirus infection - infrequent yet significant. J Viral Hepat. 2015;22(9):763-8.

Abolurin OO, Senbanjo IO, Adekoya AO, Ajibola ED. Congenital cytomegalovirus infection as an important cause of infantile cholestatic jaundice: a case report. Pan Afr Med J. 2020;36:106-8.

Engelmann G, Wenning D, Herebian D, Sander O, Dröge C, Kluge S, Kubitz R. Two Case Reports of Successful Treatment of Cholestasis with Steroids in Patients With PFIC-2. Pediatrics. 2015;135(5):1326-32.

Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG. Liver Transplantation for Progressive Familial Intrahepatic Cholestasis. Ann Transplant. 2018;23:666-73.

Swed-Tobia R, Kassis I, Weiss K, Tal G, Shaoul R, Falik-Zaccai TC, Mandel H, Meir M. Concomitant congenital CMV infection and inherited liver diseases. Eur J Med Genet. 2021;64(8):104249.